Unleash the Power of RNAa
Learn More >
Activating Genes to Combat Disease
Learn More >
We Deliver First-in-Class Therapies
We are an clinical-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells.
RNAa Technology:
RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA).
RNAa is among the limited technologies capable of stimulating the production of targeted endogenous genes.
Our Pipeline:
The Push for the Next
Generation of Therapeutics
Ractigen has a diverse pipeline covering previously undruggable diseases and monogenic disorders including oncology, neurological and neuromuscular disorders, and liver-related indications.
The pipeline explores the boundaries of our technology and pushes for the next generation of RNAa therapeutics.
Meet Our Team
Our leadership comprises a unified team of experts in RNA research and drug development, including the pioneers of RNAa technology, specialists in nucleic acid chemistry, biotech entrepreneurs, and authorities in drug discovery.
News
Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
— Peer-reviewed publication details RAG-17’s robust translation from "bench to bedside," validating the proprietary SCAD™…
Read More
